No data available for drug.
DRUG INTERACTION
No drug interaction found for methyldopa and .
carvedilol
may have an increased AV-blocking effect when combined with beta-blockers
iron sucrose
may diminish concentration of serum when combined with methyldopa
iron
may diminish concentration of serum when combined with methyldopa
iron dextran
may diminish concentration of serum when combined with methyldopa
imipramine
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
protriptyline
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
trimipramine
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
protriptyline
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
hyaluronidase
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
bromocriptine
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
mirtazapine
may decrease the antihypertensive effect when combined with alpha2-agonists
lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
lisuride
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
ergonovine
may have an increased vasoconstricting effect when combined with alpha1-agonists
cabergoline
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergocornine
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergocristine
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergotamine
may have an increased vasoconstricting effect when combined with alpha1-agonists
levalbuterol
may increase the av-blocking effect of beta-blockers
acebutolol
may increase the av-blocking effect of beta-blockers
carvedilol
may increase the av-blocking effect of beta-blockers
esmolol
may increase the av-blocking effect of beta-blockers
metoprolol
may increase the av-blocking effect of beta-blockers
levalbuterol
may enhance the AV-blocking effect of beta-blockers
acebutolol
may enhance the AV-blocking effect of beta-blockers
penbutolol
may enhance the AV-blocking effect of beta-blockers
pindolol
may enhance the AV-blocking effect of beta-blockers
propranolol
may enhance the AV-blocking effect of beta-blockers
acebutolol
may increase the effect of beta-blockers
penbutolol
may increase the effect of beta-blockers
pindolol
may increase the effect of beta-blockers
timolol
may increase the AV-blocking effect
betaxolol
may increase the AV-blocking effect
desvenlafaxine
may decrease the therapeutic effect when combined with Alpha2-Agonists
duloxetine
may decrease the therapeutic effect when combined with Alpha2-Agonists
levomilnacipran
may decrease the therapeutic effect when combined with Alpha2-Agonists
milnacipran
may decrease the therapeutic effect when combined with Alpha2-Agonists
nefazodone
may decrease the therapeutic effect when combined with Alpha2-Agonists
oracit
may increase the serum concentration
vasopressin
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
spironolactone
It may decrease the vasoconstricting effect when combined with Alpha-/Beta-Agonists
pergolide
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
clozapine
It may decrease the therapeutic effect when combined with Alpha-/Beta-Agonists
No data available for drug.
DRUG INTERACTION
methyldopa
&
No Drug Intearction Found. for methyldopa and .
carvedilol
may have an increased AV-blocking effect when combined with beta-blockers
iron sucrose
may diminish concentration of serum when combined with methyldopa
iron
may diminish concentration of serum when combined with methyldopa
iron dextran
may diminish concentration of serum when combined with methyldopa
imipramine
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
protriptyline
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
trimipramine
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
protriptyline
They may increase the vasopressor effect when combined with Alpha-/Beta-Agonists
hyaluronidase
It may increase the vasoconstricting effect when combined with Alpha-/Beta-Agonists
bromocriptine
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
mirtazapine
may decrease the antihypertensive effect when combined with alpha2-agonists
lofexidine
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
lisuride
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
ergonovine
may have an increased vasoconstricting effect when combined with alpha1-agonists
cabergoline
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergocornine
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergocristine
may have an increased vasoconstricting effect when combined with alpha1-agonists
dihydroergotamine
may have an increased vasoconstricting effect when combined with alpha1-agonists
levalbuterol
may increase the av-blocking effect of beta-blockers
acebutolol
may increase the av-blocking effect of beta-blockers
carvedilol
may increase the av-blocking effect of beta-blockers
esmolol
may increase the av-blocking effect of beta-blockers
metoprolol
may increase the av-blocking effect of beta-blockers
levalbuterol
may enhance the AV-blocking effect of beta-blockers
acebutolol
may enhance the AV-blocking effect of beta-blockers
penbutolol
may enhance the AV-blocking effect of beta-blockers
pindolol
may enhance the AV-blocking effect of beta-blockers
propranolol
may enhance the AV-blocking effect of beta-blockers
acebutolol
may increase the effect of beta-blockers
penbutolol
may increase the effect of beta-blockers
pindolol
may increase the effect of beta-blockers
timolol
may increase the AV-blocking effect
betaxolol
may increase the AV-blocking effect
desvenlafaxine
may decrease the therapeutic effect when combined with Alpha2-Agonists
duloxetine
may decrease the therapeutic effect when combined with Alpha2-Agonists
levomilnacipran
may decrease the therapeutic effect when combined with Alpha2-Agonists
milnacipran
may decrease the therapeutic effect when combined with Alpha2-Agonists
nefazodone
may decrease the therapeutic effect when combined with Alpha2-Agonists
oracit
may increase the serum concentration
vasopressin
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
spironolactone
It may decrease the vasoconstricting effect when combined with Alpha-/Beta-Agonists
pergolide
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
clozapine
It may decrease the therapeutic effect when combined with Alpha-/Beta-Agonists
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet